Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 17/20 | 0.59 |
| ▸ | CD99 | P14209 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.52 |
| ▸ | PDE2A | O00408 | 2/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.52 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21802814 | 0.92 | NT5E (0.52) | NT5ECD99ADORA3PDE2AADORA2A | |
| SCHEMBL30198810 | 0.92 | NT5E (0.52) | NT5ECD99ADORA3PDE2AADORA2A | |
| SCHEMBL21291974 | 0.92 | NT5E (0.52) | NT5ECD99ADORA3PDE2AADORA2A | |
| SCHEMBL21291984 | 0.92 | NT5E (0.54) | NT5ECD99ADORA3PDE2AADORA2A | |
| SCHEMBL30198570 | 0.91 | NT5E (0.51) | NT5ECD99ADORA3PDE2AADORA2A | |
| SCHEMBL21291967 | 0.91 | NT5E (0.51) | NT5ECD99ADORA3PDE2AADORA2A | |
| SCHEMBL21291979 | 0.91 | NT5E (0.51) | NT5ECD99ADORA3PDE2AADORA2A | |
| SCHEMBL23743770 | 0.90 | PDE2A (0.64) | NT5EPDE2A | |
| SCHEMBL21291968 | 0.89 | PDE2A (0.64) | NT5ECD99ADORA3PDE2AADORA2A | |
| SCHEMBL21291988 | 0.87 | NT5E (0.53) | NT5ECD99ADORA3PDE2AADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11701377-B2 | Methods for treating cancers by prodrugs of clofarabine | BoYen Therapeutics, Inc. (TW) | 2023-07-18 | — | — | US | disclosed |
| US-11701377-B2 | Methods for treating cancers by prodrugs of clofarabine | BoYen Therapeutics, Inc. (TW) | 2023-07-18 | — | — | US | disclosed |
| US-11701377-B2 | Methods for treating cancers by prodrugs of clofarabine | BoYen Therapeutics, Inc. (TW) | 2023-07-18 | — | — | US | disclosed |
| EP-3529254-B1 | PRODRUGS OF CLOFARABINE | WU LAURENCE I (TW) | 2023-02-22 | — | — | EP | disclosed |
| US-20210244755-A1 | METHODS FOR TREATING CANCERS BY PRODRUGS OF CLOFARABINE | BoYen Therapeutics, Inc. (TW) | 2021-08-12 | — | — | US | disclosed |
| US-20210244755-A1 | METHODS FOR TREATING CANCERS BY PRODRUGS OF CLOFARABINE | BoYen Therapeutics, Inc. (TW) | 2021-08-12 | — | — | US | disclosed |
| US-11021510-B2 | Prodrugs of clofarabine | BoYen Therapeutics, Inc. (TW) | 2021-06-01 | — | — | US | disclosed |
| US-11021510-B2 | Prodrugs of clofarabine | BoYen Therapeutics, Inc. (TW) | 2021-06-01 | — | — | US | disclosed |
| US-20200095272-A1 | PRODRUGS OF CLOFARABINE | BoYen Therapeutics, Inc. (TW) | 2020-03-26 | — | — | US | disclosed |
| US-20200095272-A1 | PRODRUGS OF CLOFARABINE | BoYen Therapeutics, Inc. (TW) | 2020-03-26 | — | — | US | disclosed |
| EP-3529254-A1 | PRODRUGS OF CLOFARABINE | Wu, Laurence I. (TW) | 2019-08-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200095272-A1 | PRODRUGS OF CLOFARABINE | CXCR2, FOLR1, ALK | NT5E 385/4885CD99 2594/4885ADORA3 298/4885 |
| US-11701377-B2 | Methods for treating cancers by prodrugs of clofarabine | FOLR1, DHFR, CBR1 | NT5E 2242/4885CD99 1871/4885ADORA3 1292/4885 |
| US-11021510-B2 | Prodrugs of clofarabine | ALK, BCL6, DHFR | NT5E 2379/4885CD99 1663/4885ADORA3 1303/4885 |
| US-20210244755-A1 | METHODS FOR TREATING CANCERS BY PRODRUGS OF CLOFARABINE | DHFR, FOLR1, ALK | NT5E 2312/4885CD99 1847/4885ADORA3 1329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.